APYX

In Q1 2026, Apyx Medical reported $12.5 million in revenue, a 36% increase in Surgical Aesthetics, and a narrowed net loss, leading to an upward revision of its full-year 2026 revenue guidance. On May 8, 2026, the company announced expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction, which resulted in a 13.54% stock gain on May 14. In May 2026, Renuvion won the NewBeauty award for 'Best Minimally Invasive Skin Tightener' for the second consecutive year, and the company showcased Renuvion and AYON at Miami Swim Week to boost awareness. For Q2 2026, Apyx Medical reported $13.9 million in revenue, exceeding estimates with 28% growth in Surgical Aesthetics, but the stock slipped after-hours due to investor concerns about near-term margin outlook and cash usage, though full-year guidance was reaffirmed. As of September 22, 2026, the stock decreased by 5.45% in the past month but increased by 41.15% over the last 12 months.